Seer, Inc. Stock

Equities

SEER

US81578P1066

Office Equipment

Market Closed - Nasdaq 04:00:00 2024-04-22 pm EDT 5-day change 1st Jan Change
1.67 USD +0.60% Intraday chart for Seer, Inc. -6.70% -13.92%
Sales 2024 * 18.94M Sales 2025 * 28.57M Capitalization 108M
Net income 2024 * -86M Net income 2025 * -86M EV / Sales 2024 * -9.28 x
Net cash position 2024 * 284M Net cash position 2025 * 251M EV / Sales 2025 * -5 x
P/E ratio 2024 *
-1.34 x
P/E ratio 2025 *
-1.42 x
Employees 147
Yield 2024 *
-
Yield 2025 *
-
Free-Float 86.96%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.60%
1 week-6.70%
Current month-12.11%
1 month-12.11%
3 months+1.83%
6 months-8.24%
Current year-13.92%
More quotes
1 week
1.61
Extreme 1.61
1.78
1 month
1.61
Extreme 1.61
2.00
Current year
1.51
Extreme 1.51
2.18
1 year
1.46
Extreme 1.455
5.65
3 years
1.46
Extreme 1.455
54.63
5 years
1.46
Extreme 1.455
86.55
10 years
1.46
Extreme 1.455
86.55
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 17-03-15
Director of Finance/CFO 56 20-04-30
Chief Operating Officer - -
Members of the board TitleAgeSince
Director/Board Member 68 17-11-30
Founder 75 17-03-15
Director/Board Member 57 18-01-31
More insiders
Date Price Change Volume
24-04-22 1.67 +0.60% 727,767
24-04-19 1.66 -5.14% 669,226
24-04-18 1.75 +3.55% 601,510
24-04-17 1.69 -3.43% 377,550
24-04-16 1.75 -2.23% 418,875

Delayed Quote Nasdaq, April 22, 2024 at 04:00 pm EDT

More quotes
Seer, Inc. is a life sciences company. The Company is engaged in developing transformative products that open a new gateway to the proteome. Its product, the Proteograph Product Suite (Proteograph), leverages its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid and large-scale access to the proteome. The Proteograph Product Suite is an integrated solution that includes consumables, an automation instrument and software. Its proprietary engineered NPs provide unbiased sampling of intact proteins across the dynamic range of the proteome, capturing molecular information at the peptide-level, including protein variants. It is focused on driving the adoption of the Proteograph by customers in the proteomics and genomics markets. The Proteograph Product Suite is an integrated solution consisting of consumables, an automation instrument, and software to perform biased, deep proteomic analysis at scale in a matter of hours.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
1.67 USD
Average target price
7 USD
Spread / Average Target
+319.16%
Consensus